Staar Surgical shares rise following analyst upgrade

Staar Surgical shares rose significantly on Tuesday following a bullish analyst update. Stifel upgraded the eyecare company from a hold to a buy rating, raising its price target from $28 to $31 per share.

Analyst Thomas Stephan noted that Staar Surgical is expected to see higher-than-anticipated sales in the first half of 2026, particularly driven by demand for its surgically implanted lenses in China. The upgrade also highlighted the company's potential as an acquisition target for larger healthcare firms and its role as a developer of new products.

While various analysts have provided differing outlooks recently—including price target adjustments from Wedbush, Jefferies, and William Blair—the company maintains a consensus rating of 'Hold' with a consensus target price of $28.45.